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http://www.sjtrem.com/content/22/1/14ORIGINAL RESEARCH Open AccessRed blood cell transfusion in septic shock - clinical
characteristics and outcome of unselected patients
in a prospective, multicentre cohort
Ragnhild G Rosland1†, Marte U Hagen1†, Nicolai Haase1, Lars B Holst2, Morten Plambech3, Kristian R Madsen4,
Peter Søe-Jensen5, Lone M Poulsen6, Morten Bestle7 and Anders Perner1*Abstract
Background: Treating anaemia with red blood cell (RBC) transfusion is frequent, but controversial, in patients with
septic shock. Therefore we assessed characteristics and outcome associated with RBC transfusion in this group of
high risk patients.
Methods: We did a prospective cohort study at 7 general intensive care units (ICUs) including all adult patients
with septic shock in a 5-month period.
Results: Ninety-five of the 213 included patients (45%) received median 3 (interquartile range 2–5) RBC units during
shock. The median pre-transfusion haemoglobin level was 8.1 (7.4–8.9) g/dl and independent of shock day and
bleeding. Patients with cardiovascular disease were transfused at higher haemoglobin levels. Transfused patients
had higher Simplified Acute Physiology Score (SAPS) II (56 (45-69) vs. 48 (37-61), p = 0.0005), more bleeding episodes,
lower haemoglobin levels days 1 to 5, higher Sepsis-related Organ Failure Assessment (SOFA) scores (days 1 and 5),
more days in shock (5 (3-10) vs. 2 (2-4), p = 0.0001), more days in ICU (10 (4-19) vs. 4 (2-8), p = 0.0001) and higher
90-day mortality (66 vs. 43%, p = 0.001). The latter association was lost after adjustment for admission category
and SAPS II and SOFA-score on day 1.
Conclusions: The decision to transfuse patients with septic shock was likely affected by disease severity and
bleeding, but haemoglobin level was the only measure that consistently differed between transfused and
non-transfused patients.
Keywords: Intensive care, Sepsis, Shock, Blood transfusion, MortalityBackground
Septic shock is characterized by inflammatory-induced
circulatory failure leading to organ failure and high mortal-
ity rates [1]. Antibiotics, source control and resuscitation
with fluids and vasopressor and inotropic agents are the
mainstay of treatment for septic shock and may be supple-
mented with transfusion of red blood cells (RBCs) in the
case of anaemia to sustain sufficient oxygen delivery [2].
The use of RBC transfusion is, however, controversial.
The Surviving Sepsis Campaign (SSC) guidelines for* Correspondence: anders.perner@regionh.dk
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unless otherwise stated.the management of severe sepsis and septic shock
distinguish between early (< 6 hours) and later (> 6 hours)
stages of septic shock. During the first 6 hours of resuscita-
tion of septic shock transfusion to a haematocrit above
30% (approx. 10 g/dl) is recommended if central venous
oxygen saturation (ScvO2) remains below 70% despite
initial fluid and vasopressor therapy. In the later stage,
transfusion is recommended when haemoglobin is less
than 7.0 g/dl to a level of 7.0 to 9.0 g/dl. In extenuating
circumstances, such as severe hypoxaemia, ischaemic cor-
onary artery disease or acute haemorrhage, patients may
be transfused at a higher level of haemoglobin [2].
The guidelines are based on two randomized clinical
trials (RCTs). The Early Goal-Directed Therapy (EGDT)
trial indicated improved outcome with a relatively liberall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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protocol [3]. In contrast, the Transfusion Requirements
in Critical Care (TRICC) trial showed no significant dif-
ference in 90-day mortality when comparing a liberal
and a restrictive transfusion strategy. However, trial re-
sults indicated lower mortality with the restrictive trans-
fusion strategy in younger and less severely ill ICU
patients [4].
As detailed description of current transfusion practice
in septic shock is lacking, our aim was to describe
current clinical practice, including patient characteris-
tics, potential triggers and outcome associated with RBC
transfusion in unselected ICU patients with septic shock.
Methods
Design
We conducted a prospective cohort study of RBC trans-
fusion of all adult septic shock patients in seven general
ICUs in four university hospitals and three regional hos-
pitals during a 5-month study period. The study was
observational representing current practice.
Ethics
The National Board of Health, the Ethics Committee of
the Capital Region and the Danish Data Protection Agency
approved the study, which was done according to the dec-
laration of Helsinki. All measurements and interventions
were clinically indicated, so consent was waived.
Patient enrolment
Two of the authors (RGR and MUH) screened all
patients admitted to five of the participating units in
the study period; in two units local investigators
screened the patients. Those included were patients
fulfilling the consensus criteria for septic shock: 1.
Documented or suspected infection. 2. Two of the fol-
lowing SIRS criteria: temperature < 36 or > 38 degrees
Celsius, leukocyte count < 4 or > 12 x 109/l, respiratory
frequency > 20 breaths/min, mechanical ventilation or
PaO2 < 4.3 kPa or heart rate > 90 beats/min. 3. Systolic
blood pressure < 90 mmHg or vasopressor infusions
after initial fluid resuscitation [5].
Both patients diagnosed with septic shock before or
after admittance to the ICU were included. Patients were
excluded for any of the following reasons: Age < 18 years,
not undergoing active treatment, burn patients and
trauma patients during the first 24 hours of ICU admit-
tance. One member of Jehovah’s Witnesses was excluded
from the study because of documented wish against
transfusion.
Data acquisition
Data were recorded for the day of admittance to the
ICU, and for all days in septic shock by RGR and MUH.If RBCs were transfused at any shock day, data were
registered for each transfusion episode. Data were regis-
tered on paper case report forms at the respective ICUs
and merged into the study database by two investi-
gators. The following baseline characteristics were re-
corded: Age, gender, type of admission, simplified acute
physiology score (SAPS) II, source of infection, pres-
ence of acute or chronic cardiovascular disease (CVD)
or chronic obstructive pulmonary disease (COPD). Car-
diovascular disease was defined as previous ischemic
heart disease, atherosclerosis (any location) or acute myo-
cardial infarction (present if noted in patient files by
the clinicians).
The daily registrations during shock included severity
organ failure assessment (SOFA) score, minimum values
of haemoglobin, arterial pH and ScvO2, highest concen-
tration of plasma lactate and value of INR, lowest mean
arterial pressure (MAP), highest heart rate (HR), max-
imum infusion rate of noradrenalin and volume of resus-
citation fluid (isotonic saline, Ringers solutions and any
colloid solutions) and volumes of blood products (RBCs,
fresh frozen plasma and platelets).
For every transfusion episode, time, RBC volume and
number of RBC units given were registered in addition
to the following characteristics two hours prior to the
transfusion: minimum values of haemoglobin, arterial
pH, ScvO2 and PaO2/FiO2, maximum doses of vasopres-
sor and inotropic agents, highest concentration of
plasma lactate, lowest MAP and highest heart rate and
if bleeding occurred as documented in patient notes.
Bleeding during surgery and 24 hours postoperatively
was not registered. If the time of RBC transfusion was
not registered in the patient’s transfusion file or observa-
tion chart, the time of delivery from the blood bank was
used instead. RBC transfusions given prior to ICU ad-
mittance, during surgery and within the first 24 hours
postoperatively were not recorded.
Finally, the number of days in shock and in ICU and
28- and 90-day mortality were recorded, the latter by the
use of the civil personal registration number in the
administrative system for Danish hospitals (GS Open).
Statistics
The primary analyses were to compare characteristics
between RBC transfused and non-transfused patients.
To describe any time-dependency or competing risk in
relation to RBC transfusion, shock characteristics and
co-interventions were compared for transfused and non-
transfused patients on each shock day from day 1 to 5.
Continuous variables were expressed as medians with
interquartile ranges (IQRs) and categorical variables as
numbers with percentages of the total. Data were ana-
lysed using Wilcoxon’s rank sum test and chi-square test.
Fisher’s exact test was used if the sample was five or
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out CVD or bleeding were compared using a univariate
mixed model allowing for correlations for multiple trans-
fusions given to the same individual.
We examined the association between RBC transfu-
sion and 90-day mortality with uni- and multivariate
logistic regression. SAPS II, SOFA-score on day 1 and
study site were used as covariates if they seemed to be
associated with 90-day mortality in univariate analysis
(p < 0.10). Medical vs. surgical patient category was
forced into the model even though the p-value for the
association with mortality was 0.12, because this charac-
teristic appeared to differ between transfused and non-
transfused patients (Table 1).
All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC) and values of p< 0.05 were
considered statistically significant. P-values between 0.01Table 1 Characteristics and outcomes of the 213
consecutive ICU patients with septic shock dependent
on RBC transfusion during shock
Characteristics All
patients
RBC
transfused
Non-
transfused
P value
Number of patients 213 95 (45) 118 (55)
Age 69 (60-77) 69 (60-76) 69 (59-77) 0.91
Female 87 (41) 38 (40) 49 (42) 0.82
Type of admission 0.03
Medical 124 (58) 64 (67) 60 (51)
Emergency surgery 82 (39) 30 (32) 52 (44)
Elective surgery 7 (3) 1 (1) 6 (5)
Focus of infection 0.51
Pulmonary 81 (38) 39 (41) 42 (36)
Gastrointestinal 68 (32) 25 (26) 43 (36)
Soft tissue 20 (9) 8 (8) 12 (10)
Urinary tract 9 (4) 6 (6) 3 (3)
Other 15 (7) 7 (7) 8 (7)
Unknown 20 (9) 10 (11) 10 (8)
SAPS II 51 (40-65) 56 (45-69) 48 (37-61) 0.0005
Acute or chronic
cardiovascular disease1
122 (57) 54 (57) 68 (58) 0.91
COPD 40 (19) 20 (21) 20 (17) 0.45
Outcomes
Days in shock 3 (2-6) 5 (3-10) 2 (2-4) < 0.0001
Days in ICU 6 (3-12) 10 (4-19) 4 (2-8) < 0.0001
28-day mortality 102 (48) 56 (59) 46 (39) 0.004
90-day mortality 114 (54) 63 (66) 51 (43) 0.0008
Data are number of patient (%) or medians (IQRs).
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR,
interquartile range; SAPS II, simplified acute physiology score II.
1Only 9 patients had acute cardiovascular disease, 5 were transfused and 4
were not.and 0.05 were interpreted with caution due to multiple
comparisons.
Handling of missing data
In general, there were very few missing data and all ana-
lyses presented were complete case analyses. All patients
were included in the multivariate analysis and we used
the obtained SAPS II and SOFA score. Thus, we did not
impute missing score components.
Results
Two-hundred-thirteen patients with septic shock were
included of who 139 were from university hospitals and
74 from regional hospitals. Their characteristics are
given in Table 1. Twenty-nine (14%) patients had at least
one bleeding episode registered and these occurred mainly
on days 1 and 2 (Table 2).
RBC transfusion
Ninety-five (45%) of the patients received a total of 398
RBC units during 315 registered RBC transfusion episodes
with a median of 3 (2-5) transfused units per patient.
Seventy-seven % of the transfusions were administrated as
single units, 20% as two units and 3% as three or more
units.
The RBC transfused group had higher SAPS II, but
there were no differences in age and the frequencies of
CVD or COPD between the groups (Table 1).
In the first 5 days of shock the transfusion frequency var-
ied between 16 - 24%. The occurrence of bleeding and
daily minimal haemoglobin concentration were the only
factors that consistently differed between RBC transfused
and non-transfused patients (Table 2). SOFA scores were
higher in RBC transfused compared to non-transfused pa-
tients on days 1 and 5 (Table 2). In contrast, there were no
differences on any days in minimum ScvO2 or maximum
dose of noradrenalin or concentration of lactate between
the groups. These data were largely unchanged by the ex-
clusion of bleeding patients (Additional file 1: Table S1).
More crystalloids and colloids were given on days 1
and 2, but there were no differences between RBC trans-
fused and non-transfused patients (Table 3). The RBC
transfused group received significantly more platelets on
days 1, 3 and 5 and significantly more fresh frozen plasma
on day 1 (Table 3).
RBC triggers
The median value of the pre-transfusion haemoglobin
was 8.1 g/dl (7.4-8.9) and did not differ over time
(Figure 1). Patients with CVD were transfused at a higher
haemoglobin level than those without CVD (Table 4). At
time of transfusion, patients with bleeding had higher
concentration of lactate and lower oxygenation ratio
compared to those without bleeding (Table 4).
Table 2 Clinical characteristics dependent on RBC transfusion on consecutive days of septic shock
Day 1 RBC No RBC P value
Number of patients (%) 34 (16) 179 (84) -
Bleeding episode, n (%) 7 (21) 0 < 0.0001
SOFA 12 (9-14) 9 (7-12) 0.0004
NA dose (max) (μg/kg/min) 0.20 (0.07-0.35) 0.15 (0.06-0.30) 0.27
Haemoglobin (min) (g/dl) 7.3 (6.8-7.9) 10.0 (8.9-11.1) < 0.0001
ScvO2 (min) (%) 68 (51-76), n = 16 71 (65-76), n = 83 0.21
Lactate (max) (mmol/l) 3.1 (1.5-7.9) 2.8 (1.7-4.6), n = 178 0.39
Day 2
Number of patients (%) 32 (17) 156 (83) -
Bleeding episode, n (%) 8 (25) 0 < 0.0001
SOFA 9 (8-13) 9 (7-13) 0.91
NA dose (max) (μg/kg/min) 0.13 (0.08-0.22) 0.15 (0.07-030) 0.49
Haemoglobin (min) (g/dl) 7.9 (7.6-8.7) 9.7 (8.9-10.5) < 0.0001
ScvO2 (min), (%) 71 (68-75), n = 21 72 (65-76), n = 68 0.85
Lactate (max) (mmol/l) 2.0 (1.3-4.1) 2.3 (1.6-3.3), n = 155 0.72
Day 3
Number of patients (%) 31 (24) 98 (76) -
Bleeding episode, n (%) 4 (13) 0 0.0003
SOFA 10 (9-14) 10 (7-12) 0.21
NA dose (max) (μg/kg/min) 0.16 (0.09-0.25) 0.13 (0.08-0.26) 0.39
Haemoglobin (min) (g/dl) 8.2 (7.4-8.5) 9.7 (9.0-10.3) < 0.0001
ScvO2 (min) (%) 67 (63-72), n = 18 72 (64-75), n = 38 0.15
Lactate (max) (mmol/l) 2.0 (1.5-3.0) 1.9 (1.4-2.6), n = 97 0.45
Day 4
Number of patients (%) 17 (17) 82 (83) -
Bleeding episode, n (%) 3 (18) 0 0.0001
SOFA 12 (9-14) 10 (8-14) 0.34
NA dose (max) (μg/kg/min) 0.13 (6-25) 0.10 (6-19) 0.43
Haemoglobin (min) (g/dl) 8.4 (7.9-8.7) 9.3 (8.5-10.0) 0.0004
ScvO2 (min) (%) 70 (65-72), n = 10 66 (63-76), n = 20 0.80
Lactate (max) (mmol/l) 1.7 (1.2-2.4) 1.7 (1.3-2.7), n = 81 0.60
Day 5
Number of patients (%) 18 (24) 58 (76) -
Bleeding episode, n (%) 4 (22) 0 0.0002
SOFA 14 (12-16) 10 (8-13) 0.01
NA dose (max) (μg/kg/min) 0.14 (0.08-0.40) 0.12 (0.04-0.20) 0.08
Haemoglobin (min) (g/dl) 7.7 (7.1-8.5) 9.5 (8.7-10.3) < 0.0001
ScvO2 (min) (%) 74 (69-78), n = 6 67 (63-77), n = 19 0.30
Lactate (max) (mmol/l) 2.3 (1.5-3.3) 1.7 (1.4-2.3) 0.33
Values are as medians (interquartile ranges) of those patients with registered data; n is given in the cells, if not all patients had the value registered.
Min, minimum; max, maximum; n, number; NA, noradrenalin; SOFA, sequential organ failure assessment; ScvO2, central venous oxygen saturation.
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39 (12%) had registered measurements of ScvO2 in the
2-hour period preceding transfusion. No patients had a
catheter for continuous ScvO2 measurement.Outcome
RBC transfused patients had more days in shock and
longer ICU stay compared to the non-transfused (Table 1).
At discharge from the study ICU 9% of patients were
Table 3 Daily use of crystalloids, colloids and blood products depending on RBC transfusion on consecutive days of
septic shock
Day 1 RBC No RBC P value
Number of patients (%) 34 (16) 179 (84) -
RBCs (ml) 490 (300-735) - -
Crystalloids and colloids (ml) 3000 (1800-4600), n = 31 3000 (1600-5000), n = 165 0.62
Platelets (ml) 350 (300-370), n = 7 350 (350-1050), n = 11 0.009
Fresh frozen plasma (ml) 550 (540-1080), n = 13 545 (531-600), n = 24 0.0004
Day 2
Number of patients (%) 32 (17) 156 (83) -
RBCs (ml) 490 (245-490) - -
Crystalloids and colloids (ml) 2000 (1250-3000), n = 29 1650 (1000-3000), n = 129 0.22
Platelets (ml) 550 (420-980), n = 4 700 (350-1050), n = 13 0.49
Fresh frozen plasma (ml) 1050 (540-1200), n = 5 600 (540-1067), n = 16 0.37
Day 3
Number of patients (%) 31 (24) 98 (76) -
RBCs (ml) 245 (245-490) - -
Crystalloids and colloids (ml) 1325 (800-2400), n = 22 1400 (900-2000), n = 71 0.91
Platelets (ml) 350 (350-1050), n = 8 350 (350-1050), n = 5 0.001
Fresh frozen plasma (ml) 540 (408-680), n = 8 540 (540-813), n = 11 0.06
Day 4
Number of patients (%) 17 (17) 82 (83) -
RBCs (ml) 245 (245-245) - -
Crystalloids and colloids (ml) 1500 (1000-2000), n = 9 1000 (500-1300), n = 41 0.40
Platelets (ml) 700 (525-1050), n = 4 350 (300-700), n = 10 0.18
Fresh frozen plasma (ml) 405 (270-540), n = 2 560 (540-600), n = 10 0.88
Day 5
Number of patients (%) 18 (24) 58 (76) -
RBCs (ml) 245 (245-490) - -
Crystalloids and colloids (ml) 500 (200-1100), n = 14 1000 (900-2000), n = 37 0.45
Platelets (ml) 350 (350-700), n = 5 1050, n = 1 0.0009*
Fresh frozen plasma (ml) n = 0 537 (524-550), n = 2 0.44
Values are as medians (interquartile ranges) of those patients with registered data; n is given in the cells, if not all patients had the value registered.
*Significantly more platelets were given in the RBC group as 5 patients received platelets vs. only 1 in the No RBC group.
RBCs, red blood cells.
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and 30% of the patients died in the ICU. The 90-day
mortality rate was 54% in the full cohort; 66% in the
RBC transfused vs. 43% in the non-transfused patients
(p = 0.0008) (Table 1).
Univariate logistic regression analyses (Additional file 1:
Table S2) showed that RBC transfusion, SAPS II and
SOFA-score at day 1 significantly associated with 90-day
mortality whereas study site did not (RBC transfusion
vs. no RBC transfusion: odds ratio (OR) for death 2.59
(95% CI 1.48 - 4.53), p = 0.0009). In the adjusted multi-
variate analysis (Additional file 1: Table S2), RBC trans-
fusion was not associated with 90-day mortality (RBCtransfusion vs. no RBC transfusion: OR for death 1.72
(95% CI 0.91 - 3.24), p = 0.10).
Discussion
The main findings in this study were that 45% of the
septic shock patients were transfused during shock and
that these patients had more bleeding episodes and
higher disease severity on admission (SAPS II and SOFA
score). Bleeding and haemoglobin concentration were
the only factors that consistently differed between trans-
fused and non-transfused throughout the course of
shock, but the majority of transfusions were given to
non-bleeding patients. Patients with bleeding had higher
Figure 1 Haemoglobin (Hb) trigger levels in septic shock. The
scatter plot depicts the Hb levels within two hours before RBC
transfusion on days of shock. The bars denote medians.
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compared to those without bleeding, but the haemoglobin
levels did not differ between the groups. The median pre-
transfusion haemoglobin value was 8.1 g/dl in all trans-
fused patients, and patients with CVD were transfused at a
higher haemoglobin level than those without CVD. Overall
RBC transfused patients also received more plasma and
platelets and had more days in shock, longer ICU stayTable 4 Differences in potential physiological triggers in
RBC-transfused patients 0-2 hours prior to transfusion
depending on cardiovascular disease or bleeding
Differences, bleeding
vs. non-bleeding
Standard
error
P value
Haemoglobin (g/dl) 0.2 0.1 0.19
pH -0.03 0.01 0.04
PaO2/FiO2 (kPa) -5.4 1.5 0.0003
ScvO2 (%) -5.2 3.3 0.12
Lactate (max) (mmol/l) 1.5 0.4 0.0005
MAP (min) (mmHg) -2 2 0.19
Heart rate (max) (beats/min) -3 3 0.38
Differences, CVD
vs. no CVD
Standard
error
P value
Haemoglobin (g/dl) 0.4 0.2 0.048
pH 0 0.02 0.90
PaO2/FiO2 -3.6 2.1 0.10
ScvO2 (%) -2.7 3.3 0.43
Lactate (max) (mmol/l) -0.7 0.4 0.23
MAP (min) (mmHg) 0 2 0.98
Heart rate (max) (beats/min) -4 5 0.40
CVD, cardiovascular disease; MAP, max, maximum; mean arterial pressure; min,
minimum; ScvO2, central venous oxygen saturation.and markedly higher 90-day mortality than those not
transfused. The association between RBC transfusion
and mortality did not persist after adjustment in the multi-
variate logistic regression analysis.
The transfusion of RBCs in non-bleeding patients
should be based on the need for increased oxygen deliv-
ery and the haemoglobin level [6]. Our findings indicate
that the haemoglobin level was the prevailing trigger fac-
tor for RBC transfusion. This observation is comparable
to those of a post hoc analysis of shock patients in a co-
hort of acute lung injury patients and those of a less
detailed study in septic shock [7,8]. Our transfusion rate
of 45% was in the higher end compared to those ob-
served in other critical care patients (25% to 53%) [9]
and in community-acquired severe sepsis (39%) [10].
The pre-transfusion value of haemoglobin of 8.1 g/dl in
our study was lower than in the previous cohorts of gen-
eral ICU patients (8.4 to 8.6 g/dl [4,11-13]), but slightly
higher than in community-acquired severe sepsis (7.7 g/dl)
[10]. Referring to the SSC guidelines, one would expect
to find lower ScvO2 and a higher haemoglobin trigger
values on day 1 compared to the following days, but
this was not the case. So RBC transfusion practice did
not appear to adhere to the SSC guidelines neither in
this nor in the previously published cohorts of patients
with septic shock [7,8].
The SSC guidelines are based on the results of two
RCTs with potentially divergent results [3,4], but neither
of these trials may fully inform ICU clinicians on when
to transfuse RBCs in the septic shock patients. TRICC
included general ICU patients after initial stabilization.
In the sub-group analysis of patients with severe sepsis
[4], liberal RBC transfusion may have increased the rela-
tive risk of death by 30%, but this did not reach statis-
tical significance. The EGDT trial showed remarkable
effects of a complex protocol in the early phase of resus-
citation of patients with severe sepsis including RBC
transfusion in the case of persistent hypoperfusion in a
single US emergency department [3]. Therefore it is dif-
ficult to assess the sole effect of RBC transfusion in ICU
patients with septic shock. Furthermore, neither of these
trials used pre-storage leukocyte-depleted RBCs, which
is now the standard in most centres. This may also have
affected the outcome [11].
RBC transfusion has been identified as a risk factor for
mortality in multiple epidemiological studies of general
ICU patients [8,12-16] and in a systematic review of co-
hort studies of RBC transfusion in critical care patients
in general [17]. However, neither Parson et al. [8] nor
the SOAP study collaborators found that RBC transfu-
sion was significantly associated with increased mortality
using multivariate analysis [14]. The same was the case
in our data, where the point estimate indicated harm by
RBC transfusion, but the confidence interval crossed 1.0.
Rosland et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2014, 22:14 Page 7 of 8
http://www.sjtrem.com/content/22/1/14Moreover when patients were matched by propensity
scoring in the SOAP cohort, RBC transfusion was asso-
ciated with improved outcome [14]. These results are
supported by data from a single, surgical ICU [15] and a
cohort of patients with community-acquired severe
sepsis from multiple ICUs [10]. It may be questioned
if any of the statistical models used are valid to ad-
just for the obvious differences between transfused and
non-transfused in cohorts of ICU patients. There are
problems at multiple levels. First, the most valid adjust-
ments are done with baseline variables. In ICU cohorts
first day SAPS II, APACHE II and SOFA scores are often
used, but these are not true baseline variables, because
they are calculated from data from the first 24 hours of
intensive care. The problem is that RBC transfusion given
in these 24 hours in ICU may influence the scores, which
is very obvious for APACHE II scoring where the lowest
haematocrit value is included. Other variables in these
scores may also be affected by any positive or negative ef-
fects of RBCs which may invalid the adjustment. Second,
neither of the scoring systems have 100% predictive
power for mortality, so that confounding by indication
may remain in spite of adjustment for disease severity
using these scores. Third, transfusion is often a repeated
intervention and the reason for transfusion may change
over time and the time ‘at risk’ also varies. Our study in-
dicate that bleeding and haemoglobin level was the main
trigger in this cohort, but also SOFA score on day 1 and
5 differed between RBC transfused and non-transfused,
whereas we observed no differences on day 2, 3 and 4.
Other unmeasured characteristics may also have differed
between the groups making it difficult to correct differing
patient characteristics at repeated transfusions over time.
Lastly, competing risk may exist as shown in our cohort,
where RBC transfused patients were more likely to re-
ceive other blood products. Controlling for all these
potential confounders may be very difficult even with
complex statistical modelling. We believe that the only
adequate method to assess the safety and efficacy of RBC
transfusion in patients with septic shock is performing
large RCTs testing different triggers and levels preferable
in multiple trials. The potential for such RCTs was shown
in patients with acute upper-gastrointestinal bleeding
where RBC transfusion at haemoglobin levels of 7 vs.
9 g/dl improved survival [18]. In patients with septic
shock, the on-going TRISS – Transfusion-Requirements
in Septic Shock – trial (NCT01485315) is to randomise
1,000 patients in 30 Scandinavian ICUs through the
Scandinavian Critical Care Trials Group [19]. The TRISS
trial will test if using haemoglobin levels of 7 vs. 9 g/dl as
RBC transfusion trigger will alter 90-day mortality and
the degree of organ failure. The interim analysis was
done in June 2013 after 90-day follow-up of 500 patients
and the trial is expected to be finalized early in 2014.Strengths of the study
The strengths of our study include prospective inclusion
of all consecutive patients at multiple university and
non-university ICUs. A specific patient group with
expected high risk/benefit was included using well-
established definitions, and follow-up was done through
the national patient registry using civil registration num-
bers, which ensured full follow-up. Using detail registration
and reporting of both baseline and time-dependent charac-
teristics allowed us to detail transfusion practice. The mor-
tality rate was high as observed in recent pragmatic trials
including patients with septic shock [20,21].Limitations of the study
The sample size was relatively small and obtained in one
country only. This was an observational study and pa-
rameters were registered from observational charts, thus
the data registration was based upon the assumption that
all observations were registered. The lack of full elec-
tronic source data may have hampered data acquisition.
Furthermore, the routine of registering the exact time for
administrating RBC varied among ICUs, and we made no
distinction between administration and prescription of
RBCs, which does not necessarily correspond in time.
Finally, blood age and the periods before and after ICU ad-
mittance are all likely to be of importance, but these data
were not included in our study due to logistical and finan-
cial reasons.Conclusions
Half of the patients received RBCs during septic shock
and these patients were more severely ill at admission
and had more bleeding episodes and more organ fail-
ures. Haemoglobin level was the only measure that con-
sistently differed between transfused and non-transfused
patients.Additional file
Additional file 1: Table S1. Clinical characteristics dependent on RBC
transfusion on consecutive days of septic shock in patients without
bleeding. Table S2. Results of the logistic regression model of risk factors
for death in ICU for patients with septic shock.Abbreviations
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